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Aneurysm-osteoarthritis syndrome (AOS) is an autosomal dominant
SMAD3mutation that is characterized by aneurysmswithin the arterial
tree and early-onset arthritis of the joints (van der Linde et al., 2012; van
der Linde et al., 2013). It is uniquely different from Marfan's syndrome
(MFS) which is a disorder of the extracellular matrix, specifically
fibrillin-1 (Judge and Dietz, 2005). In this issue of EBioMedicine, van
der Pluijm et al. dissect out the features of a whole body SMAD3 defi-
cient mouse and compares it to a Fibulin-4 deficient mouse model (ex-
tracellular matrix defect model) (Fig. 8 of paper) (van der Pluijm et al.,
2016). It is extremely interesting that while the phenotypes in aneu-
rysm formation are similar, the molecular mechanisms are quite dis-
tinct. The authors note that there were no changes in aortic stiffness
or MMP activity within the vascular smooth muscle cells (VSMCs) of
the SMAD3-deficient mice, but instead more inflammatory infiltration
of immune cells into the adventitia. Likewise, while both models show
elevation of phosphorylated SMAD2 and ERK, the downstream targets
of TGF-β signaling are decreased with SMAD3 deficiency, but have no
effect or increased signaling with Fibulin-4 deficient mice (van der
Pluijm et al., 2016).
Due to these differences in signaling, the authors suggest that block-
ade of inflammation may be a more appropriate treatment for those
with SMAD3 dysfunction. Another recent study has also concluded
that immune cells are dysfunctional with SMAD3 deficiency (Ye et al.,
2013). Currently, there are no drug therapies for the treatment of aneu-
rysms and surgery is the only option. Those that have MFS are typically
placed on a beta-blocker, angiotensin converting enzyme inhibitor
(ACEi) or an angiotensin receptor blocker (ARB) (Judge and Dietz,
2005; Habashi et al., 2006). Interestingly, those patients that havemuta-
tions within the TGF-β receptors (Loeys-Dietz syndrome, LDS), such as
TGFBRI or TGFBRII, have elevated TGF-β signaling andmay requiremed-
ications that target this pathway or downstream targets (e.g. ERK),
however this is still highly controversial (Wheeler et al., 2014;
Akhurst and Hata, 2012; Cook et al., 2015). One of the problems with
targeting TGF-β is it has both canonical and non-canonical pathways.
The canonical pathway influences the phosphorylation of SMADs
which can modulate gene expression patterns at both pre- and post-
transcription within the cell. This pathway typically inhibits the prolif-
eration of cells, however under SMAD3 deficiency, VSMCs were
shown to have increased rates of proliferation (van der Pluijm et al.,
2016). This further indicates that patients with SMAD3 mutations may
not respond well to the current drug therapies that are used for MFS
and LDS patients, and it may require further testing to determine
what drug regiment might be best for this patient population.
AOS is also a recently identified aortic disease and is tied to familial
inheritance (Wheeler et al., 2014). It is important for families to be
screened for these mutations so that proper surveillance, via ultra-
sounds, can occur. Another interesting finding from the study by van
der Pluijm et al., was the difference in survival rates between males
and females with SMAD3 deficiency (van der Pluijm et al., 2016). Fe-
males tended to have better survival than males with SMAD3 deficien-
cy, indicating that there may be gender differences. It has been well
documented that abdominal aortic aneurysms (AAAs) are sexually di-
morphic in both mice and humans with males also being more suscep-
tible to the disease (Henriques et al., 2004). It would be interesting to
see if this holds true in AOS patients as well.
This paper highlights the need for better understanding into themo-
lecular signaling pathways that give rise to aneurysms. While under
SMAD3 deficiency, TGF-β signaling is disrupted, it may require different
types of drugs to help slow the progression of aneurysms in AOS pa-
tients. With the use of these novel mouse models, hopefully cardiovas-
cular scientists will be able to bring new drugs and therapies to help
patients live better and more productive lives.
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